<DOC>
	<DOCNO>NCT01880502</DOCNO>
	<brief_summary>A randomized , double-blind , placebo-controlled , single-dose , dose escalation study ( Phase I ) evaluate tolerability pharmacokinetics Belviq adult Korean volunteer .</brief_summary>
	<brief_title>Pharmacokinetic Study Belviq Adult Korean Volunteers</brief_title>
	<detailed_description>The volunteer screen medical history , physical exam , laboratory test etc . within 4 week ( -28d~-2d ) prior day schedule take investigational product ( 1d ) . The final subject determine eligible clinical trial screening test randomize dose group Belviq 10 mg 20 mg. Twelve subject assign group ( 9 subject study drug 3 subject placebo ) , study drug placebo administer corresponding administration group . The subject discharge morning 4d completing set study schedule 72 hour administration . The subject visit final test last out-patient visiting day . Belviq progress sequentially low-dose group high-dose group . The blood sampling time pharmacokinetic evaluation follow . Blood sample pharmacokinetic evaluation : Before administration ( 0 ) , 0.5 , 1 , 1.5 , 2 , 2.5 , 3 , 3.5 , 4 , 6 , 8 , 12 , 16 , 24 , 36 , 48 72 h ( 17 time ) medication .</detailed_description>
	<criteria>1 . Subject healthy adult age 18 ~ 60 year old time screening . 2 . Subject body weight index ( BMI ) 23.0 ~ 32.0 . ☞ BMI ( kg/m2 ) = weight ( kg ) / { height ( ) } 2 3 . Subject congenital chronic disease without pathologic symptom find medical exam . Vital sign Supine SBP ( mmHg ) 90140 DBP ( mmHg ) 5090 Heart rate ( beat/min ) 4080 Respiratory rate ( breaths/min ) 818 4 . Subject determine eligible accord result clinical laboratory test like serum test , hematologic test , blood chemistry test , urine test etc . vital sign , electrocardiography , physical exam etc . perform screen exam . SBP ( mmHg ) 90140 DBP ( mmHg ) 5090 Heart rate ( beat/min ) 4080 Respiratory rate ( breaths/min ) 818 5 . Subject decide participate voluntarily give write Informed consent comply instruction listen fully understand detailed explanation trial . 1 . Subject clinically significant liver , kidney , neurologic , immunologic , respiratory , endocrine disease hematologic·oncologic disease , cardiovascular disease psychiatric disease ( mood disorder , compulsive disorder etc . ) medical history ( include subject hepatitis virus case liver disease ) . 2 . Subject history gastrointestinal disease ( Crohn 's disease , ulcer , acute chronic pancreatitis etc . ) gastrointestinal surgery ( except simple appendectomy hernia operation ) affect absorption study drug . 3 . Subject hypersensitivity reaction drug ( aspirin , antibiotic etc . ) history clinically significant hypersensitivity reaction . 4 . Subject history drug abuse test positive abused drug urine drug screen test ( performed screen Day 1 ) . 5 . Subject take prescribed drug oriental medicine within 2 week prior first medication overthecounter ( OTC ) drug vitamin within 1 week prior first medication paracetamol 48 hour prior take study drug ( however , subject include criterion meet accord discretion investigator ) . 6 . Subject participate another study receive medication within 3 month prior first medication day ( 3 month judge period medication ) . 7 . Subject history use follow drug Fenfluramine/dexfenfluramine phentermine Drug may increase risk valvulopathy primary pulmonary hypertension ( Cyproheptadine , Trazodone , Nefazodone , Amoxapine , tricyclic antidepressant , mirtazapine , pergolide , ergotamine , methysergide ) . 8 . Subject receive whole blood transfusion ( 500 mL ) within 3 month prior first medication blood transfusion within 1 month prior first medication . 9 . Subject continually drink ( excess 28 units/week ( 21 unit/week woman ) , 1 unit = 10 g pure alcohol ) abstain drink 48 hour prior study drug administration hospitalization period . 10 . Subject smoke 3 cigarette one day abstain smoke 48 hour prior study drug administration hospitalization period . 11 . Subject take caffeinecontaining food within 48 hour prior first medication , abstain take hospitalization period . 12 . Subject test positive HbsAg , HCV Ab , HIV Ab test . 13 . Subject peculiar diet , vegetarian consumes food may affect drug metabolism ( e.g . St. John 's Wort ) . 14 . Subject serious change dietary habit activity 4 week prior study drug administration . 15 . Subject his/her partner willing use appropriate contraceptive trial period 28 day termination study ( woman , exclusion criterion include pregnant breastfeed woman woman confirm pregnant pregnancy test ) . 16 . Subject judge eligible accord discretion investigator reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Healthy , Volunteers</keyword>
</DOC>